ArticleFrontiers in endocrinology2025
Differences in growth in prepubertal children with definite growth hormone deficiency, short stature unresponsive to stimulation tests, and idiopathic short stature treated with recombinant human growth hormone: a retrospective study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Growth Hormone Treatment Response and Machine Learning-Based Prediction in Idiopathic GHD and ISS: Analysis of the Korean LG Growth Study.Clinical endocrinology · 2026Observational
- Impact of growth hormone treatment on childhood growth patterns in Kermanshah: A retrospective cohort study.Journal of education and health promotion · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Growth hormone stimulation tests are crucial in diagnosing growth hormone deficiency (GHD) in children; however, their limited reliability and inconsistent thresholds pose diagnostic challenges. A proposed subclassification distinguishes definite GHD (dGHD), short stature unresponsive to stimulation (SUS), and idiopathic short stature (ISS). This study aims to assess whether these categories are distinguishable at baseline and differ in response to recombinant human growth hormone (rhGH) therapy, particularly in terms of near adult height (NAH) outcomes. Methods: This retrospective cohort study analyzed data from 3,939 prepubertal children in the KIGS (Pfizer International Growth Database) who received rhGH therapy and reached NAH. Patients were classified into three groups: dGHD (GH peak <8 ng/mL with identifiable genetic, functional, or anatomical causes), SUS (GH peak <8 ng/mL without an identifiable cause), and ISS (GH peak ≥8 ng/mL). Multivariable regression analyses assessed the association of various factors with NAH outcomes. Results: Children with SUS showed baseline differences from those with dGHD but responded similarly to rhGH, with a height SDS increase of 0.13 for SUS and 0.12 for dGHD. In contrast, ISS children exhibited a smaller response (0 SDS increase). At the end of rhGH treatment, 74% of dGHD and SUS patients achieved a normal height (≥-2 SDS), compared to 65% of ISS patients. The most significant predictors of NAH included height at treatment initiation and mid-parental height, particularly in ISS patients. Conclusion: Despite initial differences, children with SUS responded similarly to rhGH as dGHD patients, while ISS patients had a less favorable response. These findings support the importance of subclassifying short stature conditions to refine diagnostic processes, enhance treatment approaches, and improve growth outcome predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.